Kristen A. Feemster, MD, MPH, MSHP

Director, Medical Affairs
Merck & Co., Inc

Poster(s):

• 540 - A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children with Sickle Cell Disease (PNEU–SICKLE)
  Sunday, April 24, 2022

  3:30 PM – 6:00 PM US MT

• 553 - Safety and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Children Living with HIV: A Phase 3 Trial (PNEU-WAY PED)
  Sunday, April 24, 2022

  3:30 PM – 6:00 PM US MT